Sentences with phrase «including immunotherapy»

Over the past 5 years, a number of new pharmacologic treatments for advanced melanoma have been introduced, including immunotherapy, targeted agents (BRAF and MEK inhibitors), and oncolytic viral therapy.

As New Jersey's only National Cancer Institute - designated Comprehensive Cancer we offer your patients access to the most advanced treatment options including immunotherapy, precision medicine, and clinical trials.

Traditional treatments are invasive and can impair the quality of life of patients, underscoring the need for alternative therapeutic strategies, including immunotherapy.

It's clear this is not going to cure every patient, but treatments that include immunotherapy are more effective than other options.

The scientists expect a multi-pronged approach to cancer treatment in the near term that will include immunotherapy but may also include chemotherapy, radiation and surgery.

We are trialling new therapies including immunotherapies, targeted therapies and personalised medicine diagnostics.

Not exact matches

Just two weeks or so before PICI's debut, Johns Hopkins opened its own institute for cancer immunotherapy, with a $ 125 million gift from donors, including billionaires Michael Bloomberg and Sidney Kimmel.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.

The institute, which includes over 40 laboratories and more than 300 researchers, said the research would focus on modifying a patient's own immune system T - cells to target a tumor, studying ways to boost patient response to current immunotherapy drugs.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

By comparing the results to cells from paired normal tissue, researchers get a detailed molecular picture of the tumor environment, including the types and activity levels of T cells that are critical to the immunotherapy response.

A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.

This includes determining whether the drugs should be used earlier on in cancer treatment, finding biomarkers to predict response, and combining immunotherapy with other treatments.

She notes that biotech firms are investing heavily in immunotherapy research, and about 40 percent of the roughly 6,000 cancer clinical trials taking place in the United States today include some form of immunotherapy.

Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.

Past winners have included the discovery of the Higgs boson, cancer immunotherapy, and the first quantum machine.

Because those organoids include stroma, a scaffold of connective tissue essential for tumor growth, they may prove better for studying therapies that target the stroma, such as cancer immunotherapy.

Creticos says his team has also begun studies of other non-injectible forms of immunotherapy, including ragweed allergy drops, and treatment applications where the allergen is lightly pricked or inserted into the middle layers of the skin.

His additional appointments include: head of the Swim Across America / Ludwig Collaborative Laboratory; associate director of the Ludwig Center for Cancer Immunotherapy; and director of the Parker Institute for Cancer Immunotherapy at MSK.

«Injectable immunotherapies that use programmable biomaterials as a powerful vehicle to deliver targeted treatment and preventative care could help fight a whole range of deadly infections, including common worldwide killers like HIV and Ebola, as well as cancer,» said Wyss Institute Founding Director Donald Ingber, M.D., Ph.D. who is also Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and Professor of Bioengineering at Harvard SEAS.

The results of the study were published this week in the journal Nature Medicine from researchers at Penn's Abramson Cancer Center, including senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research in the ACC, the University of Maryland School of Medicine, and Adaptimmune Therapeutics plc (Adaptimmune).

«Our results support the further study and possible development of IL - 33 as adjuvants in vaccinations against pathogens, including in the context of antitumor immunotherapy,» says Weiner.

Merck CEO Kenneth Frazier explained today in The Wall Street Journal that the firm aims to rebound from recent failures and devote more resources to the company's most promising efforts, including cancer immunotherapy and diabetes research.

Wherry, together with his colleagues in the Parker Institute for Cancer Immunotherapy at Penn, are involved in multiple checkpoint - related trials, in melanoma, lung cancer, renal cell carcinoma, and others, including combining checkpoint blockade with radiation.

It's hoped this latest insight will lead to the widespread use of antigen - specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves» disease and systemic lupus erythematosus (SLE).

Nearly 300 medical professionals, patients, caregivers and advocates attended the 8th Annual Ruesch Center Symposium on December 1, listening to lectures on topics including precision medicine, immunotherapy, proton therapy and molecular imaging.

«To understand the factors behind T - cell - receptor binding to peptides will have major impact on biomedical developments, including vaccine design and immunotherapy.»

But, if a child is classified as high - risk, the survival rate falls to approximately 50 percent even with an aggressive treatment plan that includes high - dose chemotherapy, surgery, stem cell transplant, radiation and immunotherapy.

Other experimental approaches include implanting beta cells in protective capsules to prevent rejection and immunotherapy to preserve the pancreas's ability to make insulin.

And while immunotherapies typically include less intrusive side effects than chemotherapy, those side effects, when they happen, can be life - threatening.

Kaufman, who authored «The Melanoma Book: A Complete Guide to Prevention and Treatment,» says new immunotherapy treatments at Rutgers Cancer Institute — including the recently FDA - approved drug Imlygic — are creating new hope for patients diagnosed with melanoma.

We provide access to the latest medicines and technology, as well as the most advanced clinical trials including novel personalized targeted therapies including precision medicine and immunotherapy - some that are only offered at NCI - designated Comprehensive Cancer Centers like ours.

AMSBIO has launched a range of new TIGIT receptor products including a Jurkat cell line, Homogeneous assay kits and recombinant proteins for immunotherapy research

To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.

The symposium features presentations by Philippa Marrack and John Kappler talking on the T cell repertoire; William Paul on interleukin 4 as a prototypic immunoregulatory cytokine; Timothy Springer on lymphocyte trafficking; Pamela Bjorkman on structural studies of MHC and MHC - related proteins, and Jack Strominger on peptide presentation by class I and II MHC proteins; Thierry Boon on genes coding for tumor rejection antigens, including the first tumor antigen, MAGE - 1; and Philip Greenberg on the modification of T cells for adoptive therapy by retroviral - mediated gene insertion Since then, the symposia series has attracted leading immunologists in the cancer vaccine and antibody fields, providing them with a comprehensive view of the promises and challenges in the development of cancer immunotherapies.

Due to the aggressive nature of AML, this disease usually requires intensive treatment, which may include chemotherapy, radiation therapy, immunotherapy and stem cell transplantation.

The inauguaral month featured a series of five webinars from leading experts in the field, including Kunle Odunsi, M.D., Ph.D., Carl H. June, M.D., Elizabeth Jaffee, M.D., Jedd D. Wolchok, M.D., Ph.D., and Philip Greenberg, M.D., who provided first - hand perspectives on the impact immunotherapy is having on cancer patient treatment.

Researchers have reported cases in which immunotherapies attacked vital organs, including the colon, liver, lungs, kidney, and pancreas, with some patients experiencing acute, rapid - onset diabetes after receiving the treatments.

The Clinical Accelerator network includes approximately 80 of the world's leading physician - scientists with expertise in tumor immunology and cancer immunotherapy clinical trials, immune monitoring, and correlative research.

With a team of over 200 researchers, Sanford Research is comprised of eight groups that bridge bench, translational and clinical research including: Cancer Biology and Immunotherapies, Pediatrics and Rare Diseases, Diabetes, Cellular Therapies and Stem Cell Biology, Enabling Technology, Environmental Influences on Health and Disease, Genetics and Genomics, and Population Health.

A collaborative group including the CRI Cancer Immunotherapy Consortium (CIC), the Association for Cancer Immunotherapy (CIMT) Immunoguiding Program (CIP), and scientists at Stanford University launch the Minimal Information About T cell Assays (MIATA) Project, the first systematic effort to establish a framework for reporting immune monitoring data from T cell assays used in clinical trials, with the goal of fostering reliability of data to facilitate meaningful interpretation, comparison, and meta - analysis across clinical trials.

Aside from atezolizumab, immunotherapies in this class include avelumab (Bavencio); pembrolizumab (Keytruda); and nivolumab (Opdivo).

Asterias maintains an extensive global intellectual property portfolio including broad issued claims to fundamental platform technologies including, but not limited to, scalable growth of pluripotent stem cells, methods of production and compositions of matter for several hESC - derived therapeutic cell types, and cellular immunotherapy using the telomerase antigen.

Current clinical trials include combination of intrahepatic embolization and a radiosensitizer in patients with uveal melanoma and liver - only metastases, a phase I trial that evaluates a combination therapy of BCG with ipilimumab in Stage III / IV melanoma, and several landmark international trials including a phase II trial that evaluates combination immunotherapy with nivolumab & ipilimumab.

A team of Hopkins researchers has long been involved in immunotherapy research, including on pioneering clinical trials.

The Company's pipeline includes cancer immunotherapies against clinically - validated targets, such as CX - 072, a PD - L1 - targeting Probody therapeutic wholly owned by CytomX, and BMS - 986249, a CTLA -4-targeting Probody therapeutic partnered with Bristol Myers Squibb.

The first generation of immunotherapies, including immune checkpoint inhibitors and cancer vaccines, have been limited by the proportion of patients who benefit, and by the depth and duration of response in those that do.

In the ensuing months, the two companies have published detailed, promising animal studies of their immunotherapies, including preclinical efficacy studies in animal models of human synucleinopathies.